When assessing patients with suspected prostate cancer metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated PSA1
As the #1 utilized PSMA PET imaging agent in the US, PYLARIFY® is the clear standard in PSMA PET2

The incidence of prostate cancer is rising and resulting mortality rates remain significant3

Approximately 248,530 new prostate cancer cases will be diagnosed in 2021

new prostate cancer cases will be diagnosed in 20243

Accurate initial assessment of a patient's disease is critical because high-risk PCa is more likely to be advanced at diagnosis and/or relapse than low-risk PCa4-6

5-year relative survival rate for patients diagnosed with localized prostate cancer approaches 100%, however, if distant metastasis is present at the time of diagnosis, the 5-year survival rate has been reported to be 32%7

5-year survival rates of localized, regional, and distant prostate cancer
5-year survival rates of localized, regional, and distant prostate cancer

Standard imaging offers limited accuracy in PCa assessment, potentially compromising therapeutic decision-making8,9

  • Although bone scans and CT scans can detect bone metastases, they lack sensitivity for early lesion detection10
  • CT scans and MRIs depend on size to detect lesions, and are therefore less likely to detect metastatic tumors between 4 mm and 8 mm12,13
  • Standard imaging offers limited utility in detecting recurrent lesions at PSA levels <1.0 ng/mL11
  • Bone remodeling in response to treatment may lead to false positives on MRI images12
PSMA PET can detect what conventional imaging did not14

Tom Boike, MD, MMM, discusses the limitations of conventional imaging for prostate cancer compared to the advances of PSMA PET imaging.

PET imaging* has the potential to improve disease localization compared to standard imaging, thus enhancing therapeutic decision-making8,9,15

PSMA PET/CT can detect  lesions between 4 mm and  8 mm, and therefore has a  higher detection rate12,13

Because up to 80% of nodal metastases in PCa are smaller than 8 mm in size, PSMA PET/CT is a promising imaging modality12

PSMA PET/CT is also effective at lower PSA levels; the rate of detection of nodal metastases has been reported to be 46% when PSA was <0.2 ng/mL12

*With an appropriate tracer and combined with CT or MRI.

PSMA PET imaging improves disease assessment

which reduces the risk of undertreatment (leading to disease spread) and overtreatment (leading to unnecessary toxicity or surgery)16,17

Learn more

Actor portrayal

PSMA PET imaging helps identify clear next steps1,10,12,18-23

Ben Lowentritt, MD, FACS, recounts scenarios where PSMA PET imaging changed the course of patient care.

CT=computed tomography; MRI=magnetic resonance imaging; PCa=prostate cancer; PET=positron emission tomography; PSMA=prostate-specific membrane antigen.

See PYLARIFY data in patients with high-risk PCa who were candidates for initial definitive therapy

See trial results in patients with biochemically recurrent prostate cancer

Learn how PYLARIFY works

Find an imaging center near you


PYLARIFY (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.

Radiation Risks

Diagnostic radiopharmaceuticals, including PYLARIFY, expose patients to radiation. Radiation exposure is associated with a dose-dependent increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.


PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:

  • with suspected metastasis who are candidates for initial definitive therapy.
  • with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.


  1. PYLARIFY [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company.
  2. Data on file. Bedford, MA: Progenics Pharmaceuticals, Inc.; 2024.
  3. Key statistics for prostate cancer. American Cancer Society. Accessed March 25, 2024. https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
  4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer. V.3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed April 1, 2024. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
  5. Wang Z, Ni Y, Chen J, et al. The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. World J Surg Oncol. 2020;18(1):42. doi:10.1186/s12957-020-01824-9
  6. Chang AJ, Autio KA, Roach M 3rd, Scher HI. High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol. 2014;11(6):308-323. doi:10.1038/nrclinonc.2014.68
  7. Cancer stat facts: prostate cancer. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Accessed November 21, 2022. https://seer.cancer.gov/statfacts/html/prost.html
  8. Hofman MS, Lawrentschuk N, Francis RJ, et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208-1216. doi:10.1016/S0140-6736(20)30314-7
  9. Rousseau E, Wilson D, Lacroix-Poisson F, et al. A prospective study on 18F-DCFPyL PSMA PET/CT imaging in biochemical recurrence of prostate cancer. J Nucl Med. 2019;60(11):1587-1593. doi:10.2967/jnumed.119.226381
  10. Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296:44-55. doi:10.1148/radiol.2020191689
  11. Taneja SS. Imaging in the diagnosis and management of prostate cancer. Rev Urol. 2004;6(3):101-113.
  12. Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA PET? Ther Adv Med Oncol. 2019;11:1-14. doi:10.1177/1758835919876828
  13. Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with 18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206(1):52-61. doi:10.1097/JU.0000000000001698
  14. Durack JC, Alva AS, Preston MA, et al. A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): a subanalysis of disease staging changes in PCa pts with recurrence of metastases on conventional imaging. Presented at: 2021 ASCO Genitourinary Cancers Symposium: February 11-13, 2021.
  15. Li R, Ravizzini GC, Gorin MA, et al. The use of PET/CT in prostate cancer. Prostate Cancer Prostatic Dis. 2018;21(1):4-21. doi:10.1038/s41391-017-0007-8
  16. Park SY, Zacharias C, Harrison C, et al. Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology. 2018;288(2):495-505. doi:10.1148/radiol.2018172232
  17. Gorin MA, Rowe SP, Patel HD, et al. Prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: results of a prospective, phase II, single center study. J Urol. 2018;199(1):126-132. doi:10.1016/j.juro.2017.07.070
  18. Mena E, Lindenberg ML, Turkbey IB, et al. 18F-DCFPyL PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. J Nucl Med. 2020;61(6):881-889. doi:10.2967/jnumed.119.234799
  19. Werner RA, Derlin T, Lapa C, et al. 18F-labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics. 2020;10(1):1-16. doi:10.7150/thno.37894
  20. Petersen LJ, Zacho HD. PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review. Cancer Imaging. 2020;20(1):1-8. doi:10.1186/s40644-020-0290-9
  21. Ceci F, Fanti S. PSMA PET/CT imaging in prostate cancer: why and when. Clin Transl Imaging. 2019;7:377-379. doi:10.1007/s40336-019-00348-x
  22. Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575-584. doi:10.1007/s11307-015-0866-0
  23. Szabo Z, Mena E, Rowe SP, et al. Initial evaluation of [18F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol Imaging Biol. 2015;17(4):565-574. doi:10.1007/s11307-015-0850-8